Navigation Links
Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)
Date:11/26/2007

LONDON, November 26 /PRNewswire/ -- Daval International Limited, a UK private company, announces MHRA and IRB (Ethics Committee) approval of a London based Phase IIB trial of AIMSPRO(R), its hyperimmune caprine serum derivative.

This double-blind placebo-controlled cross-over study will seek to detect a beneficial effect on bladder function in patients with Secondary Progressive Multiple Sclerosis, following open-label observations over several years in a number of informed consent, "compassionate basis" patients.

AIMSPRO has an "export only" listing on the Australian Registry of Therapeutic Goods and a TGA Orphan Status Designation for the treatment of Krabbe's disease. An IND application is being lodged for a further MS trial in the United States.

AIMSPRO is a frozen medication, given as a 1ml sub-cutaneous injection every 4 days. It is believed to have a pronounced and sustained anti-inflammatory action with an associated, novel effect of lowering sodium channel triggering voltages in nerve fibres. MHRA applications for two further clinical trials are to be lodged within the next 3months.

Daval International Ltd. has recently been accepted as a member of the Association of the British Pharmaceutical Industry. "APBI"

Daval International Limited

Daval International Limited is a privately owned British pharmaceutical company, which, since 2001, has been developing an immunologically active human and veterinary medication derived from goat serum. Some 20.000 doses of Aimspro have been administered, mainly to human subjects with multiple sclerosis, with an excellent safety and tolerance profile.


'/>"/>
SOURCE Daval International Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
3. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
4. Arrow International Files and Mails Definitive Proxy Materials
5. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
6. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
7. Viragen International to Reverse Split Its Common Stock
8. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
9. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Biosafety and Biosecurity International Conference 2007 to be held in Abu Dhabi from November 12 to 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... 200 of the top radiation centers in 16 countries, has reached its 20th ... SDX® is now in routine use at top universities including University of Pennsylvania, ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed ... Manager Regulatory Solutions, in a one hour live webinar on Thursday, August ... in China for drugs and medical devices. Specifically, for medical devices, the NMPA has ...
(Date:7/18/2020)... MILWAUKEE (PRWEB) , ... July 16, 2020 , ... “We ... at Third Wave Bioactives. “It’s the only technology of its kind on the market ... flavor of onions with the protective capacity of traditional cultured ingredients, creating a natural ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , ... sciences and food industries, is pleased to announce that Charles Galea has joined ... Development. , Charles is an accomplished and results-driven sales executive with over 10 ...
Breaking Biology Technology:
(Date:9/3/2020)... NEW YORK (PRWEB) , ... September 03, 2020 ... ... for real world data, today announced that an extensive third-party assessment of the ... secure and compliant when measured against federal security regulations. The comprehensive evaluation reviewed ...
(Date:8/26/2020)... ... August 25, 2020 , ... ... company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, a ... its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic solution in ...
(Date:8/26/2020)... ... , ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, ... list is the most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions ... reported three-year revenue growth of 71 percent. , The Inc. 5000 list represents ...
Breaking Biology News(10 mins):